RegulatoryGuideline · final
Type VII Veterinary Master File for Research and Development and Risk Reviews
🇺🇸 FDA · Mon 17 Aug 2026
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for industry (GFI) #260 entitled "Type VII Veterinary Master File for Research and Development and Risk Reviews." This guidance describes FDA's current thinking regarding the use of Type VII Veterinary Master Files (Type VII VMFs). Type VII VMFs are appropriate for research and development of animal cells, tissues, and cell- and tissue-based products (ACTPs), gene therapies, and heritable intentional genomic alterations (IGAs) in animals.
Official guideline text: FDA ↗
Brief written by VigiEye from the company's press release. Claims are the company's own. AI-assisted; check the source before acting.
More Regulatory
All →
RegulatoryCompany releaseBeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
BeyondSpring, Inc. · Fri 13 Nov 2026
RegulatoryCompany releaseImricor starts US launch of NorthStar iMR system after paediatric FDA clearances
🇺🇸 Imricor Medical Systems, Inc. · Fri 13 Nov 2026
RegulatoryCompany releaseBeyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
🇺🇸 Beyond Air, Inc. (XAIR) · Fri 13 Nov 2026
RegulatoryCompany releaseFDA sets 10 March 2027 goal date for Intellia's one-time hereditary angioedema gene-editing therapy
🇺🇸 Intellia Therapeutics, Inc. (NTLA) · Fri 13 Nov 2026
RegulatoryCompany releaseBeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
🇺🇸 BeyondSpring Inc. (BYSI) · Fri 13 Nov 2026
RegulatoryCompany releaseFDA grants NeOnc Type B meeting on accelerated approval path for intranasal NEO100
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Fri 13 Nov 2026